These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology. Reale M; D'Angelo C; Costantini E; Di Nicola M; Yarla NS; Kamal MA; Salvador N; Perry G J Alzheimers Dis; 2018; 62(1):467-476. PubMed ID: 29439355 [TBL] [Abstract][Full Text] [Related]
4. Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase. Batool S; Nawaz MS; Greig NH; Rehan M; Kamal MA Antiinflamm Antiallergy Agents Med Chem; 2013; 12(2):129-35. PubMed ID: 23360257 [TBL] [Abstract][Full Text] [Related]
5. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study. Mazumder MK; Choudhury S Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161 [TBL] [Abstract][Full Text] [Related]
6. Assessment of novel azaanthraquinone derivatives as potent multi-target inhibitors of inflammation and amyloid-β aggregation in Alzheimer's disease. Wang J; Li W; Qin J; Wang L; Wei S; Tang H Bioorg Chem; 2019 Mar; 83():477-486. PubMed ID: 30448726 [TBL] [Abstract][Full Text] [Related]
7. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier. Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737 [TBL] [Abstract][Full Text] [Related]
8. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Lane RM; Potkin SG; Enz A Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515 [TBL] [Abstract][Full Text] [Related]
9. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. Li L; Xu S; Liu L; Feng R; Gong Y; Zhao X; Li J; Cai J; Feng N; Wang L; Wang X; Peng Y J Alzheimers Dis; 2017; 56(4):1403-1417. PubMed ID: 28157092 [TBL] [Abstract][Full Text] [Related]
11. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Vukic V; Callaghan D; Walker D; Lue LF; Liu QY; Couraud PO; Romero IA; Weksler B; Stanimirovic DB; Zhang W Neurobiol Dis; 2009 Apr; 34(1):95-106. PubMed ID: 19162185 [TBL] [Abstract][Full Text] [Related]
12. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Darreh-Shori T; Vijayaraghavan S; Aeinehband S; Piehl F; Lindblom RP; Nilsson B; Ekdahl KN; Långström B; Almkvist O; Nordberg A Neurobiol Aging; 2013 Nov; 34(11):2465-81. PubMed ID: 23759148 [TBL] [Abstract][Full Text] [Related]
13. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. Lee M; McGeer E; McGeer PL Neurobiol Aging; 2015 Jan; 36(1):42-52. PubMed ID: 25169677 [TBL] [Abstract][Full Text] [Related]
14. CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice. Zhu Y; Hou H; Rezai-Zadeh K; Giunta B; Ruscin A; Gemma C; Jin J; Dragicevic N; Bradshaw P; Rasool S; Glabe CG; Ehrhart J; Bickford P; Mori T; Obregon D; Town T; Tan J J Neurosci; 2011 Jan; 31(4):1355-65. PubMed ID: 21273420 [TBL] [Abstract][Full Text] [Related]
15. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. Mushtaq G; Greig NH; Khan JA; Kamal MA CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511 [TBL] [Abstract][Full Text] [Related]
17. Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid beta peptide and interleukin-1beta. Kim MS; Sung MJ; Seo SB; Yoo SJ; Lim WK; Kim HM Neurosci Lett; 2002 Mar; 321(1-2):105-9. PubMed ID: 11872267 [TBL] [Abstract][Full Text] [Related]
18. Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation. Zha GF; Zhang CP; Qin HL; Jantan I; Sher M; Amjad MW; Hussain MA; Hussain Z; Bukhari SN Bioorg Med Chem; 2016 May; 24(10):2352-9. PubMed ID: 27083471 [TBL] [Abstract][Full Text] [Related]
19. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Reale M; Iarlori C; Gambi F; Feliciani C; Isabella L; Gambi D Neuropharmacology; 2006 Apr; 50(5):606-13. PubMed ID: 16445950 [TBL] [Abstract][Full Text] [Related]
20. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]